IP Library Patent Application 18732415
Patent Application
App. No. 18/732,415

Data-Driven Personalized Breast CAD and Health-Tracking System

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/732,415
Abstract

Systems and methods for risk-based breast cancer screening. The breast cancer screening techniques can identify and monitor women who may otherwise later be diagnosed with symptomatic and/or later-stage breast cancer. A personalized breast CAD and health-tracking system is provided that can differentiate pathological changes from normal changes in breast tomosynthesis images. A breast progression predictor can be a generative model that receives input breast images including past images captured at a past timepoint and current images captured at a current timepoint. The model uses the past images to generate predicted images for the current timepoint. Differences between the predicted images and the current images can be used to determine a likelihood of pathological change in the current images. When a pathological change is detected. The system can incorporate a broad spectrum of patient non-image information to further enhance and personalize the prediction of breast progression.

Claims (46)

1 . A method for differentiating pathological change from normal aging in breast images, comprising:

receiving input breast images at a breast progression predictor, wherein the input breast images include first images captured at a first timepoint and second images captured at a second timepoint;

encoding the first images to a first latent vector;

generating a predicted latent vector at an age diffusion module, based on a healthy breast latent space, the first latent vector, and a time interval between the first timepoint and the second timepoint;

decoding the predicted latent vector to generate predicted images at the second timepoint;

identifying a difference between the second images and the predicted images; and

determining, based on the difference, a likelihood of pathology in the second images.

2 . The method of claim 1 , wherein generating the predicted latent vector at the age diffusion module comprises determining a number of diffusion cycles based on the time interval and performing the number of diffusion cycles on the first latent vector.

3 . The method of claim 1 , further comprising encoding the second images to a second latent vector.

4 . The method of claim 3 , further comprising determining a distance between the second latent vector and the predicted latent vector.

5 . The method of claim 4 , wherein determining the likelihood of pathology includes determining the likelihood based on the distance, wherein a greater distance value indicates a greater risk value.

6 . The method of claim 1 , wherein the likelihood of pathology in the second images includes a risk of cancer.

7 . The method of claim 1 , further comprising displaying the predicted images and the second images in a user interface.

8 . The method of claim 7 , further comprising identifying an area of pathological change in the second images and highlighting the area in the second images in the user interface.

9 . The method of claim 1 , further comprising receiving multimodality patient data at the breast progression predictor, and embedding the multimodality patient data in a third latent vector.

10 . The method of claim 9 , wherein generating the predicted latent vector further comprises generating the predicted latent vector based on the third latent vector.

11 . A system for differentiating pathological change from normal aging in breast images, comprising:

a breast progression predictor configured to receive input breast images, including first images captured at a first timepoint and second images captured at a second timepoint, the breast progression predictor including:

an encoder configured to encode the first images to a first latent vector,

a healthy breast latent manifold representing normal breast image latent space at various ages,

an age diffusion module configured to generate a predicted latent vector based on the healthy breast latent manifold, the first latent vector, and a time interval between the first timepoint and the second timepoint, and

a decoder configured to decode the predicted latent vector to generate predicted images at the second timepoint;

wherein the breast progression predictor is further configured to:

identify a difference between the second images and the predicted images, and

determine, based on the difference, a likelihood of pathology in the second images.

12 . The system of claim 11 , wherein the age diffusion module is further configured to:

determine a number of diffusion cycles based on the time interval, and

perform the number of diffusion cycles on the first latent vector to generate the predicted latent vector.

13 . The system of claim 11 , wherein the encoder is further configured to encode the second images to a second latent vector.

14 . The system of claim 13 , wherein the breast progression predictor is further configured to:

determine a distance between the second latent vector and the predicted latent vector, and

determine the likelihood of pathology based on the distance, wherein a greater distance value indicates a greater risk value.

15 . The system of claim 14 , wherein the breast progression predictor is further configured to determine a predicted speed of progression of the pathology.

16 . The system of claim 11 , wherein the breast progression predictor is further configured to identify an area of pathological change in the second images, and further comprising a user interface configured to display the predicted images and the second images, and to highlight the area of pathological change in the second images.

17 . The system of claim 11 , wherein the encoder is a first encoder and further comprising a second encoder, wherein the breast progression predictor is further configured to receive multimodality patient data, and the second encoder is configured to encode the multimodality patient data in a third latent vector.

18 . The system of claim 17 , wherein the breast progression predictor is further configured to generate the predicted latent vector based on the third latent vector.

19 . The system of claim 11 , wherein the breast progression predictor is further configured to receive multimodality patient data, and wherein the encoder is further configured to embed the multimodality patient data in a third latent vector.

20 . An apparatus, comprising:

a computer processor for executing computer program instructions; and

a non-transitory computer-readable memory storing computer program instructions executable by the computer processor to perform operations comprising:

receiving input breast images at a breast progression predictor, where the input breast images include first images captured at a first timepoint and second images captured at a second timepoint;

encoding the first images to a first latent vector;

generating a predicted latent vector at an age diffusion module, based on a healthy breast latent space, the first latent vector, and a time interval between the first timepoint and the second timepoint;

decoding the predicted latent vector to generate predicted images at the second timepoint;

identifying differences between the second images and the predicted images; and

determining, based on the differences, a likelihood of pathology in the second images.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 069172/0436 Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC
Reel/Frame 075503/0086 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 14, 2024
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 069172/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2024
From: SHI, BIBO; KSHIRSAGAR, ASHWINI; CHEN, JIN-LONG; ZHANG, XIANGWEI
To: HOLOGIC, INC.
Reel/Frame 067622/0700 →